Literature DB >> 23054102

Up-front hepatic resection for metastatic colorectal cancer results in favorable long-term survival.

Sulaiman Nanji1, Sean Cleary, Paul Ryan, Maha Guindi, Subani Selvarajah, Hassan Al-Ali, Paul Grieg, Ian McGilvary, Bryce Taylor, Alice Wei, Carol-Anne Moulton, Steven Gallinger.   

Abstract

BACKGROUND: Hepatic metastasis from colorectal cancer (CRC) is best managed with a multimodal approach; however, the optimal timing of liver resection in relation to administration of perioperative chemotherapy remains unclear. Our strategy has been to offer up-front liver resection for patients with resectable hepatic metastases, followed by post-liver resection chemotherapy. We report the outcomes of patients based on this surgical approach.
METHODS: A retrospective review of all patients undergoing liver resection for CRC metastases over a 5-year period (2002-2007) was performed. Associations between clinicopathologic factors and survival were evaluated by the Cox proportional hazard method.
RESULTS: A total of 320 patients underwent 336 liver resections. Median follow-up was 40 (range 8-80) months. The majority (n=195, 60.9%) had metachronous disease, and most patients (n=286, 85%) had a major hepatectomy (>3 segments). Thirty-six patients (11%) received preoperative chemotherapy, predominantly for downstaging unresectable disease. Ninety-day mortality was 2.1%, and perioperative morbidity occurred in 68 patients (20.2%). Actual disease-free survival at 3 and 5 years was 46.2% and 42%, respectively. Actual overall survival (OS) at 3 and 5 years was 63.7% and 55%, respectively. Multivariate analysis identified four factors that were independently associated with differences in OS (hazard ratio; 95% confidence interval): size of metastasis>6 cm (2.2; 1.3-3.5), positive lymph node status of the primary CRC (N1 (2.0; 1.0-3.8), N2 (2.4; 1.2-4.9)), synchronous disease (2.1; 1.3-3.5), and treatment with chemotherapy after liver resection (0.42; 0.23-0.75).
CONCLUSIONS: Up-front surgery for patients with resectable CRC liver metastases, followed by chemotherapy, can lead to favorable OS.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23054102     DOI: 10.1245/s10434-012-2424-1

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  17 in total

Review 1.  Role of cetuximab in first-line treatment of metastatic colorectal cancer.

Authors:  Miguel Jhonatan Sotelo; Beatriz García-Paredes; Carlos Aguado; Javier Sastre; Eduardo Díaz-Rubio
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

2.  Multidisciplinary approach as the key factor in the management of liver metastases from colorectal cancer.

Authors:  Jacopo Giuliani; Marina Marzola
Journal:  J Gastrointest Cancer       Date:  2013-12

3.  Synchronous resections of primary colorectal tumor and liver metastasis by laparoscopic approach.

Authors:  Tan To Cheung; Ronnie Tung Ping Poon
Journal:  World J Hepatol       Date:  2013-06-27

4.  Risk Factors for Unresectable Recurrence After Up-Front Surgery for Colorectal Liver Metastasis.

Authors:  Daisuke Hokuto; Takeo Nomi; Satoshi Yasuda; Takahiro Yoshikawa; Kohei Ishioka; Takatsugu Yamada; Takahiro Akahori; Kenji Nakagawa; Minako Nagai; Kota Nakamura; Shinsaku Obara; Hiromichi Kanehiro; Masayuki Sho
Journal:  World J Surg       Date:  2018-03       Impact factor: 3.352

Review 5.  Treatment strategies for colorectal carcinoma with synchronous liver metastases: Which way to go?

Authors:  Peter Ihnát; Petr Vávra; Pavel Zonča
Journal:  World J Gastroenterol       Date:  2015-06-14       Impact factor: 5.742

6.  The Impact of a Hepatobiliary Multidisciplinary Team Assessment in Patients with Colorectal Cancer Liver Metastases: A Population-Based Study.

Authors:  Jennie Engstrand; Nikolaos Kartalis; Cecilia Strömberg; Mats Broberg; Anna Stillström; Tobias Lekberg; Eduard Jonas; Jacob Freedman; Henrik Nilsson
Journal:  Oncologist       Date:  2017-05-26

7.  Prevalence of hypoxia and correlation with glycolytic metabolism and angiogenic biomarkers in metastatic colorectal carcinoma.

Authors:  S T Lee; V Muralidharan; N Tebbutt; P Wong; C Fang; Z Liu; H Gan; J Sachinidis; K Pathmaraj; C Christophi; A M Scott
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-10-30       Impact factor: 9.236

Review 8.  Assessment of the reporting of quality and outcome measures in hepatic resections: a call for 90-day reporting in all hepatectomy series.

Authors:  Michael E Egger; Joanna M Ohlendorf; Charles R Scoggins; Kelly M McMasters; Robert C G Martin
Journal:  HPB (Oxford)       Date:  2015-07-30       Impact factor: 3.647

Review 9.  Designing liver resections and pushing the envelope with resections for hepatic colorectal metastases.

Authors:  Mary L Guye; Hans F Schoellhammer; Louisa W Chiu; Joseph Kim; Lily L Lai; Gagandeep Singh
Journal:  Indian J Surg Oncol       Date:  2013-07-12

10.  Liver resection after chemotherapy and tumour downsizing in patients with initially unresectable colorectal cancer liver metastases.

Authors:  Nicolas Devaud; Zaheer S Kanji; Neesha Dhani; Robert C Grant; Hassan Shoushtari; Pablo E Serrano; Sulaiman Nanji; Paul D Greig; Ian McGilvray; Carol-Anne Moulton; Alice Wei; Steven Gallinger; Sean P Cleary
Journal:  HPB (Oxford)       Date:  2013-08-09       Impact factor: 3.647

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.